Baidu
map

JAMA Netw Open:心脏最喜欢乐观!15项研究23万人分析发现:乐观降低35%心血管病风险

2019-09-30 xujing 中国循环杂志

乐观应该是心脏最喜欢的性格。

乐观应该是心脏最喜欢的性格。

近日,一项纳入15项研究涉及近23万名人的研究再次证实乐观的人心脏更健康,乐观可以预防心脏病发作、中风和过早死亡。

研究者发现,与悲观主义者相比,乐观主义者患心脏病风险要低35%,死亡风险降低14%。

研究者说,这种身心联系在所有年龄段都存在,乐观主义可能是一种人生资产。

研究还发现,一个人的想法越乐观,他患心脏病或死亡的风险就越小。

为什么积极、乐观的人生态度直接或间接地有助于预防疾病。

研究者分析,乐观的人更善于解决问题,能更快地找到解决办法,他们更容易实现目标,他们也更关注自身的健康。

此外,乐观主义者有更健康的生活习惯,,可能有良好的饮食和锻炼习惯,他们不太可能吸烟。

越来越多的数据也表明,乐观可能有直接的生物效益,而悲观可能损害健康,这种生物学联系已经被证明与其他一些心理危险因素有关,如抑郁症。

作者认为,乐观也可能通过降低炎症和改善新陈代谢发挥神奇作用。

同期述评中也指出,这与更多的体力活动、更健康的饮食和一系列其他健康的生活方式行为有关,乐观促进健康的机制涉及生物学和行为学机制。

研究者分析了15项研究,包括229 391名参与者,其中10项研究报告了心血管事件的数据,9项研究报告了全因死亡率的数据。平均随访13.8年(2~40年)。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734175, encodeId=94d21e34175ac, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Feb 24 15:59:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728153, encodeId=ae621e281536a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 06 21:59:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648804, encodeId=f4dd164880498, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Sun Jun 21 01:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644791, encodeId=f5511644e9197, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu May 14 00:59:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373595, encodeId=987e3e359573, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 06 22:03:22 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-02-24 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734175, encodeId=94d21e34175ac, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Feb 24 15:59:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728153, encodeId=ae621e281536a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 06 21:59:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648804, encodeId=f4dd164880498, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Sun Jun 21 01:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644791, encodeId=f5511644e9197, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu May 14 00:59:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373595, encodeId=987e3e359573, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 06 22:03:22 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-03-06 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734175, encodeId=94d21e34175ac, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Feb 24 15:59:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728153, encodeId=ae621e281536a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 06 21:59:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648804, encodeId=f4dd164880498, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Sun Jun 21 01:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644791, encodeId=f5511644e9197, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu May 14 00:59:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373595, encodeId=987e3e359573, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 06 22:03:22 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2020-06-21 yaanren
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734175, encodeId=94d21e34175ac, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Feb 24 15:59:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728153, encodeId=ae621e281536a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 06 21:59:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648804, encodeId=f4dd164880498, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Sun Jun 21 01:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644791, encodeId=f5511644e9197, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu May 14 00:59:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373595, encodeId=987e3e359573, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 06 22:03:22 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1734175, encodeId=94d21e34175ac, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Feb 24 15:59:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728153, encodeId=ae621e281536a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 06 21:59:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648804, encodeId=f4dd164880498, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Sun Jun 21 01:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644791, encodeId=f5511644e9197, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu May 14 00:59:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373595, encodeId=987e3e359573, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 06 22:03:22 CST 2019, time=2019-10-06, status=1, ipAttribution=)]
    2019-10-06 天地飞扬

    学习

    0

相关资讯

Nature:别再说我内向了,这都是基因的错!

人有内向外向之分,你很容易就能把他们区分开来。在人群里,你能从热切的眼神以及滔滔不绝的话语中,感受到外向者不断迸发出的能量。而内向者经常会避免眼神直接交流,似乎是更愿意躲在自己的小世界中。7月13日,发表在顶级学术期刊《自然》上的一篇研究彻底为内向者正了名——来自多所科研机构的研究人员共同发现,基因决定了我们看待世界的方式。

Saudi Med J:焦虑性格在过敏性鼻炎患者中的影响研究

最近,有研究人员评估了过敏性鼻炎患者中的抑郁和焦虑水平,并调查了抑郁和焦虑症状与抑郁和焦虑性格之间的关系。研究是代表性的,在2017年和2018年之间进行,包括了101名AR患者和74名健康对照。研究人员对所有参与者进行了贝克抑郁症量表(BDI)、贝克焦虑量表(BAI)和TEMPS-A评估。研究发现,患者的BAI和BDI得分均值鼻对照组显著更高(p=0.016和p=0.001)。在AR患者中,抑郁

ABO血型那点事儿

不少人认为血型就是A型、B型、O型、AB型嘛。这样的认识比较片面。血型是指血液成分(包括红细胞、白细胞、血小板)表面的抗原类型,通常所说的血型是指红细胞膜上特异性抗原类型,根据抗原类型的不同分为不同的血型系统,目前已知的有35个红细胞血型系统,而与临床关系最密切和大家最为熟悉的是ABO血型系统。今天我们就来聊聊大家关心的ABO血型那点事儿。ABO血型ABO血型是根据红细胞膜上是否存在抗原A与抗原B

血型和性格到底有没有关系?华西专家这样说……

相信许多人在网上都看到过这样的贴子,据说有学者提出了“人因血型不同,而具有各自不同的气质;同一血型,具有共同的气质”的论断。A型的人:内向保守、多疑焦虑、富感情、缺乏果断性、容易灰心丧气……(小编这么富有革命的乐观精神的人,居然说我多疑焦虑?!)B型的人:外向积极、善交际、感觉灵敏、轻诺言、好管闲事……(好!管!闲!事!?)O型的人:胆大、好胜、喜欢指挥别人、自信、意志坚强、积极进取……(喜欢,指

癌症与性格到底是什么关系?

性格千千万,你为何要选择“癌症性格”?

人工智能技术可通过眼球运动判断性格

人们常说眼睛是心灵的窗户。一个国际研究团队日前利用人工智能技术,实现通过观察眼球运动来判断性格。

Baidu
map
Baidu
map
Baidu
map